La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FibroGen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FibroGen..

FibroGen (NASDAQ:FGEN) Azioni, Catena delle Opzioni

FIBROGEN INC

FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

FibroGen Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) with a Buy and maintains $10 price target.

News

Price Target

Reiteration

Analyst Ratings

FGEN

HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 115.15 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $2.74 million which beat the analyst consensus estimate of $2.00 million by 36.95 percent. This is a 95.10 percent decrease over sales of $55.90 million the same period last year.

Earnings

Earnings Beats

FibroGen Q1 EPS $0.05 Beats $0.02 Estimate, Sales $2.74M Beat $2.00M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.10. 
The market awaits FibroGen's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 21.8% drop in the share price on the subsequent day.
Here's a look at FibroGen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.30</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-22.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746821173_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of FibroGen were trading at $0.3194 as of May 08. Over the last 52-week period, shares are down 74.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FGEN/earnings">To track all earnings releases for FibroGen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of FibroGen's Earnings

FibroGen Announces Publication Of Results From Phase 1 Monotherapy Study Of FG-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer In Journal of Clinical Oncology; Says Initiation Of Phase 2 Monotherapy Dose Optimization Study Of FG-3246 In mCRPC Expected By Mid-2025

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKBA

APDN

BCLI

DYAI

IPSC

LENZ

SCNX

SHPH

VERO

Longevity Health Holdings, Inc. - Common Stock

XAGE

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

WIIM

FibroGen shares are trading lower. The company reported Q4 financial results.

FibroGen Q4 EPS From Continuing Operations $(0.08), Revenue From Continuing Operations $3.100M

<h3>Companies Reporting Before The Bell</h3>
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $1.68 per share on revenue of $597.66 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is likely to report earnings for its fourth quarter. 
• CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $50.11 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $20.21 million. 
• NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) is projected to report earnings for its fourth quarter. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $1.81 billion. 
• Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $81.72 million. 
• Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.74 million. 
• Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is likely to report earnings for its fourth quarter. 
• Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $116.41 million. 
<h3>Companies Reporting After The Bell</h3>
• DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is likely to report earnings for its fourth quarter. 
• Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) is expected to report earnings for its fourth quarter. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report earnings for its first quarter. 
• Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is expected to report earnings for its fourth quarter. 
• Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) is estimated to report earnings for its first quarter. 
• Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is expected to report quarterly loss at $0.11 per share on revenue of $42.51 million. 
• Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $40.84 million. 
• Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $3.77 million. 
• FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its fourth quarter. 
• FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.20 per share on revenue of $24.91 million. 
• Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is likely to report earnings for its fourth quarter. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report quarterly loss at $1.25 per share on revenue of $21.61 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is estimated to report earnings for its fourth quarter. 
• Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $33.60 million. 
• RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) is expected to report earnings for its first quarter. 
• Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $59.09 million. 
• Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is likely to report quarterly loss at $0.05 per share on revenue of $102.46 million. 
• Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $46.55 million. 
• Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $244.87 million. 
• Lithium Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $48.40 million. 
• Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is projected to report quarterly loss at $0.22 per share on revenue of $35.55 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPS

BLTE

CBAT

CODA

DMAC

FINV

HITI

HROW

HYPR

INSE

KODK

LNZA

LPRO

NRXP

NXPL

QFIN

QTRX

RBOT

RFIL

RILY

SAIC

SGMO

SNDA

Earnings Scheduled For March 17, 2025

FibroGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) stock is trading higher on Thursday. The company&nbsp;announced the sale of its China subsidiary to AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43842973/fibrogen-announces-the-sale-of-fibrogen-china-to-astrazeneca-for-approximately-160-million" rel="noreferrer noopener">approximately $160 million</a>.
&#8220;Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables us to continue progressing the clinical development program for FG-3246, our first-in-class, CD46 targeting antibody-drug conjugate, and FG-3180, our companion PET imaging agent, in mCRPC,&#8221; said Thane Wettig, Chief Executive Officer of FibroGen.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43065029/astrazeneca-aims-to-restore-trust-with-new-leadership-in-china-amid-scandal-and-sales-decline" rel="noreferrer noopener">AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline</a>
FibroGen will receive an enterprise value of $85 million plus FibroGen net cash in China at closing, estimated to be approximately $75 million, totaling roughly $160 million. The transaction is expected to close by mid-2025.
AstraZeneca will obtain all rights to roxadustat for anemia in chronic kidney disease in China. A regulatory decision for chemotherapy-induced anemia is pending.
FibroGen maintains its rights to roxadustat in the U.S. and in all markets not licensed to Astellas. The company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome.
The company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.
In relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $0.9 million, referred to in the Appraisal Opinion relate to cancer drugs, <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" rel="noreferrer noopener">Imfinzi and Imjudo</a>.
A fine of one and five times unpaid importation taxes may also be levied if AstraZeneca is found liable (amounting to around $0.9 million to $4.5 million). Reuters notes the update reassures analysts and investors that the business impact would be minor.
AstraZeneca&#8217;s China sales fell 1% on a reported basis to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41907137/astrazeneca-lifts-2024-forecast-on-better-than-expected-q3-performance-says-it-takes-china-invest" rel="noreferrer noopener">$1.36 billion (-3% at CER)</a>.
Price Action: FGEN stock is up 21.6% at $0.68 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43852190/southern-company-q4-utility-growth-boosts-revenue-but-rising-costs-weigh-on-profit" target="_blank" rel="noreferrer noopener">Southern Company Q4: Utility Growth Boosts Revenue, But Rising Costs Weigh on Profit</a></li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Large Cap

Health Care

Trading Ideas

General

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FibroGen shares are trading higher after the company announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

<ul>
<li>&nbsp;Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million</li>
<li>Upon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure
<ul>
<li>Company's cash runway extended into 2027</li>
</ul>
</li>
<li>Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025</li>
<li>Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024</li>
</ul>

FibroGen Announced The Sale Of Its China Subsidiary To AstraZeneca For Approximately $160M

Management

FibroGen Announced The Appointment Of David DeLucia As CFO Effective December 16, 2024

FibreGen shares are trading higher. The stock may be moving on continued strength following a Q3 earnings beat reported on Tuesday.

Guidance

FibroGen Reiterates Full Year Net Product Revenue Guidance Of $135M-$150M

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.38) by 55.26 percent. The company reported quarterly sales of $46.333 million which beat the analyst consensus estimate of $34.763 million by 33.28 percent. This is a 15.45 percent increase over sales of $40.134 million the same period last year.

FibroGen Q3 2024 GAAP EPS $(0.17) Beats $(0.38) Estimate, Sales $46.333M Beat $34.763M Estimate

ABOS

ABSI

ACTG

AENT

AIOT

AIRG

ALIT

ALTG

AMTX

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

Comments

FibroGen

FibroGen (FGEN) Opzioni

FibroGen (NASDAQ:FGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO